Loading clinical trials...
Loading clinical trials...
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS
Conditions
Interventions
Trifarotene 0.005 % Topical Cream
AKLIEF®
+1 more
Locations
14
United States
Site 10011
West Covina, California, United States
Site 10001
Brandon, Florida, United States
Site 10003
Fort Lauderdale, Florida, United States
Site 10004
Miami, Florida, United States
Site 10005
Miramar, Florida, United States
Site 10002
Tampa, Florida, United States
Start Date
September 19, 2022
Primary Completion Date
May 9, 2023
Completion Date
May 9, 2023
Last Updated
September 26, 2024
NCT07205107
NCT05891795
NCT06501560
NCT03883269
NCT07469228
NCT07348978
Lead Sponsor
Teva Pharmaceuticals USA
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions